Table 4.
Percentage of abnormal lipid profile in control individuals (n=21) vs. patients with hypopituitarism (n=42) (above), and in control individuals (n=21) vs. patients with pituitary diseases (n=99) (below).
| Control n=21 | Patients with hypopituitarism n=42 | p | |
|---|---|---|---|
|
TChol
≥2000 mg/L (≥200 mg/dL) |
n=3 14% |
n=18 43% |
0.025 |
|
HDLC
<400 mg/L (<40 mg/dL) |
n=5 24% |
n=7 17% |
0.509 |
|
LDLC
>1000 mg/L (>100 mg/dL) |
n=10 48% |
n=23 55% |
0.601 |
|
TGs
>1500 mg/L (>150 mg/dL) |
n=7 33% |
n=19 45% |
0.364 |
|
HDLC/TChol
<0.2 |
n=1 5% |
n=3 7% |
0.759 |
| Control n=21 | Patients with pituitary diseases n=99 | p | |
|
TChol
≥2000 mg/L (≥200 mg/dL) |
n=3 14% |
n=38 38% |
0.037 |
|
HDLC
<400 mg/L (<40 mg/dL) |
n=5 24% |
n=17 40% |
0.170 |
|
LDLC
>1000 mg/L (>100 mg/dL) |
n=10 48% |
n=54 56% |
0.504 |
|
TGs
>1500 mg/L (>150 mg/dL) |
n=7 33% |
n=40 40% |
0.551 |
|
HDLC/TChol
<0.2 |
n=1 5% |
n=5 5% |
1.000 |
Statistical evaluation was performed by the two-sided ratio comparison test. Statistical significance was determined at the level of p<0.05. Statistically significant differences are shaded.